NCT01237054 2026-02-06
Imaging in MGUS, SMM and MM
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
23 trialsNCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT03631043 2025-12-19
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT05565638 2025-09-25
PROFAST
Dana-Farber Cancer Institute
Phase NA Completed
NCT03951220 2025-08-19
LOOMIS
Oxford University Hospitals NHS Trust
Completed
NCT02916771 2025-08-11
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00112827 2025-06-06
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT02316106 2025-04-27
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT03792763 2025-02-11
DEFENCE
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT04615572 2024-10-28
Screening to Improve Survival in AL Amyloidosis
Tufts Medical Center
Completed
NCT02903381 2023-06-13
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02279394 2023-06-09
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01302886 2020-12-17
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
Novartis
Phase 2 Completed
NCT02492750 2020-03-25
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT01441973 2018-01-23
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Bristol-Myers Squibb
Phase 2 Completed
NCT01884688 2017-04-17
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma
University of Arkansas
Phase 2 Completed
NCT01955395 2017-03-16
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
Massachusetts General Hospital
Phase NA Completed
NCT00099047 2016-12-30
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01718899 2016-09-28
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
OncoPep, Inc.
Phase 1 Completed
NCT00919139 2015-04-03
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
SWOG Cancer Research Network
Completed
NCT01219010 2015-01-19
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT01222286 2014-05-09
KIRMONO
Innate Pharma
Phase 2 Completed
NCT00480363 2013-07-31
QUIREDEX
PETHEMA Foundation
Phase 3 Completed